Rivia raises USD 15M Series A to bring clinical trials into the agentic AI era
18.03.2026
Zurich-based start-up Rivia has secured USD 15 million in Series A funding to accelerate its mission to modernize clinical trials with agentic AI. The round was led by Earlybird, with participation from Defiant, Speedinvest, Amino Collective, and Nina Capital.
 |
 |
Clinical trials are increasingly complex, with data volumes growing over 400% in the past decade. Yet many biotech and pharma operators still rely on fragmented spreadsheets and outdated systems, spending thousands of human hours on repetitive validation, reconciliation, and monitoring tasks.
The Venture Kick alumnus Rivia’s platform addresses this challenge by unifying clinical trial data, applying scientific logic at scale, and embedding AI agents directly into operational workflows. Over the past three years, the company has developed a reusable intelligence layer for clinical trials, now powering 40 trials across the US and Europe.
Its data engine integrates thousands of heterogeneous data files in real-time, applies trial-specific scientific logic through a proprietary library, and delivers harmonized data into review workflows, enabling proactive decision-making. On this foundation, Rivia is deploying AI agents, starting with Spark, which transforms natural language into publication-ready clinical visualizations instantly. Upcoming agents will focus on data quality monitoring, deviation detection, and structured, auditable actions.
The goal is ambitious yet concrete: to cut clinical trial costs by up to 50% by replacing repetitive manual tasks with scalable agentic systems. The Series A funding will support team growth, scale product development, and expand Rivia’s presence internationally, with a particular focus on the US market.
Rivia founders Tiago Kieliger and Eric Scalfaro
The Venture Kick alumnus Rivia’s platform addresses this challenge by unifying clinical trial data, applying scientific logic at scale, and embedding AI agents directly into operational workflows. Over the past three years, the company has developed a reusable intelligence layer for clinical trials, now powering 40 trials across the US and Europe.
Its data engine integrates thousands of heterogeneous data files in real-time, applies trial-specific scientific logic through a proprietary library, and delivers harmonized data into review workflows, enabling proactive decision-making. On this foundation, Rivia is deploying AI agents, starting with Spark, which transforms natural language into publication-ready clinical visualizations instantly. Upcoming agents will focus on data quality monitoring, deviation detection, and structured, auditable actions.
The goal is ambitious yet concrete: to cut clinical trial costs by up to 50% by replacing repetitive manual tasks with scalable agentic systems. The Series A funding will support team growth, scale product development, and expand Rivia’s presence internationally, with a particular focus on the US market.
Rivia founders Tiago Kieliger and Eric Scalfaro